Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

biotech_invest 100 posts  |  Last Activity: Sep 21, 2016 3:55 PM Member since: Mar 5, 1998
  • biotech_invest biotech_invest Sep 21, 2016 3:55 PM Flag

    LOL! What is next sourse you pumpers will use to pump this scam? May be some "dazibao"? :-)
    One idiot digged some unknown website with some nonsense information that contain Prana name and now is trying to pump the stock by mentioning that Prana has some PAH and drug market for PAH is expected to exceed $3 billion :-) There is nothing to discuss, guys. Just BS

    Sentiment: Strong Sell

  • Reply to

    Every Portfolio Needs Some Pran

    by kadaicher1 Sep 15, 2016 11:49 AM
    biotech_invest biotech_invest Sep 21, 2016 12:29 PM Flag

    well, I can say it because I have several biotechs in my portfolio that started Ph3 but still have no any drugs approved by FDA. And share prices are not showing any stable and continous rising over the courses of their trials. Just a few examples: CARA (pain druh in Ph3), CLSN (new cancer therapy in Ph3), ANTH (lupus drug in Ph3, also has exocrine pancreatic insufficiency drug in Ph3). One more example: recently I bought VBLT in my portfolio: this biotech has very good anti-cancer approach and their drug also in Ph3. Just open 2 years chart for all those biotechs (that all have very strong science basis) and you will everything but not the "continous rising over the course of the trial".
    BTW so-called "new PD drug" firstly must pass Ph1, then Ph2 and only after may be will go to Ph3. Results of Ph3 (if any) will be released in 2023-25 i.e. too long period of time to have any influence on PRAN pps during next 2-3 years.
    So, kad, don't be naive in investing in biotech. Lift of PCH for Ph3 HD will induce only modest pps spike but it will not continue rising over the course of the trial. When trial results release is very close (ANTH CHABLIS-SC1 trial may be in Q4, 2016 and CARA CR845 in Q2, 2017) you can hope for some run up. For AD and HD drugs it can happen even for Ph2 trials. That is all.
    Indeed, the lift of PCH for Ph3 HD will create very good opportunity to make money on PRAN but it will be very long story.

    Sentiment: Strong Sell

  • Reply to

    Every Portfolio Needs Some Pran

    by kadaicher1 Sep 15, 2016 11:49 AM
    biotech_invest biotech_invest Sep 19, 2016 11:46 AM Flag

    well, I can agree with +30% short-term pps spike in case of PCH lift with 250 mg PBT2 daily dosing :-) It will be $6.50 from current $5 pps :-) Or $1.08 in before 1:6 RS prices :-)
    I also hope that you agree that Ph3 HD will take at least 3-4 years and tons of money. Only naive investors will believe that "run up" will start immediately after PCH lift and will continue during next 3-4 years. Most likely it will be stable pps level with slow decline to $5 and below and then (in 2019-2020) we should see run up to $10-12. PD drug will not play big role in pps before it show promising results in Ph2 (after 2020). Prana will need more money during next 3-4 years so will again do public offering and dilute stock.
    Any way, lift of PCH will again create perfect opportunity again to make money with this scam biotech. Will wait for it :-)

    Sentiment: Strong Sell

  • Reply to

    Every Portfolio Needs Some Pran

    by kadaicher1 Sep 15, 2016 11:49 AM
    biotech_invest biotech_invest Sep 16, 2016 12:55 PM Flag

    come on, kad, the return that is promised by you can't be big even if PRAN lift PCH for Ph3 HD with 250 mg PBT2 daily dose :-) You pumpers are always promising the lift of PCH as some "binary event" for this scam biotech but it's just ugly lie. You always forget to say that the results of this Ph3 HD will be released only after 3-4 years i.e. in 2020 or later. Prana will spent all cash already in first 1-2 years after Ph3 start and then they will dilute the stock to make money.
    So, may be the lift of PCH will induce some pps spike but nor more than 20-30% from current pps. After this spike we will see slow decline to $5 and below. Nobody will pay $10-12 for biotech that will show results in 2020 and those results can be not good (just look at NVAX and see what will happen if Ph3 HD fail).
    So, it's better not have PRAN but just wait and then play a game.

    Sentiment: Strong Sell

  • Promise from Prana pumpers that "PCH can be lifted any day from now" already longs 3 months. Well, may be for PRAN management it's better to keep the feeding of holders by promises and have a happy life with good salaries. They have enough cash for next 3-4 years of such status quo situation. Question is will Prana holders keep their shares for next 2-3 years if no any real events? It's very unlikely. Some of them already start to understand that this 18 months period of preparation of Complete Response smells fishy.

    Sentiment: Strong Sell

  • opportunity to sell this scam higher $5 :-) Today buyers will again wait for promised $18 and finally will get -50% losses. It's normal situation for naive foolish investors :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Sep 8, 2016 3:26 PM Flag

    LOL! Now Shoulson becomes a savior of Prana :-) Just because he sits on the Prana board and gets salary check each month :-)
    Come on, kad, nobody will buy such BS :-)
    Prana needs to provide special safety package for PBT2 that will be used by data monitoring committee in Phase 3 HD to monitor patient safety and treatment efficacy data. For example, if PBT2 induces any adverse events of serious type that were observed for chloroquine (subacute myelo-optic neuropathy) then the DMC will recommend termination of the study. BTW, CQ-induced retinopathy is reversible only at early stage and it was rare observed for 250 mg daily dose.
    "Baseline evaluation for patients beginning treatment with a chloroquine derivative should include a complete eye examination by an eye care professional, retinal photography for follow-up comparisons, and Visual field testing with a white pattern. Central visual field assessment should test the central 10° of vision with a white test target (such as Humphrey 10-2 program)."

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Sep 7, 2016 4:31 PM Flag

    well, let's just take 1 year: Sep 10, 2015 - pps $5.16 and Sep 07, 2016 - pps $4.76. -8% losses for buying and holding PRAN during 1 year. Slightly better than -20% for last 1 month :-)
    Do you think that Prana will sent a Complete Response before 2 years anniversary of PCH? Well, they still have 4 months for preparation of package :-) FDA will response during 30 days so may be we will know it before end of this year.
    BTW, TauRx LMTX® failed to achieve its coprimary endpoints in 220 subjects with behavioural variant frontotemporal dementia (bvFTD). They still have some hope for monotherapy of AD but looks like that TAI is not feasible approach to cure AD. Sure that Tanzi will immediately stop to advertise PBT2 as a compound that decrease tau aggregation :-)
    But it's sad news for current and future AD/FTD patients - no cure during next 10-15 years.

    Sentiment: Strong Sell

  • BUY Prana and wait for lift PCH that can happen "any day from now" :-) They are just ugly liars. 18 months period of Prana inability to send a Complete Response says very simple truth: they don't have any arguments to persuade FDA to lift PCH for 250 mg PBT2 daily dosing of HD patients. And now they are planning Europe trial in hope that it will save PRAN pps from complete crash below $1.

    Sentiment: Strong Sell

  • Reply to

    Planning a confirmation trial.

    by kadaicher1 Sep 2, 2016 5:28 AM
    biotech_invest biotech_invest Sep 2, 2016 2:37 PM Flag

    kad, Shoulson participation in Prana Phase 3 HD trial with PBT2 is not a warranty of trial success :-)
    He agreed to participate because Prana pays him good money for this. Nothing more. PBT2 showed some positive sign in Ph2 HD but most likely it was an effect of small numbers i.e. statistical noise. Phase 3 HD (if any) most likely will fail to repeate any positive trends that were observed in Ph2 HD.
    Any way, a lift of PCH will create a huge intrigue and great possibility to make money on PRAN again. So, I'm waiting for this event. Switch to Europe (in case of Prana inability to persuade FDA to lift PCH) is less interesting event but it also welcomed. Infinite silence and empty updates from Prana CEO are not welcomed. They must say and do something real. Prana holders will not wait 1-2 years more, they will sell and run already after 2 years of PCH.

    Sentiment: Strong Sell

  • Reply to

    Planning a confirmation trial.

    by kadaicher1 Sep 2, 2016 5:28 AM
    biotech_invest biotech_invest Sep 2, 2016 12:27 PM Flag

    looks like kad becomes more and more delusional :-) LOL! "Prana have perhaps the most successful movement disorder trials doc on the planet" :-) Shoulson never invented any drugs that really cure any diseases. HD is still incurable: "medications are available to help manage the symptoms of Huntington's disease, but treatments can't prevent the physical, mental and behavioral decline associated with the condition".
    PBT2 is just a fake drug and will fail in Ph3 HD trial (if any) with or without Shoulson help.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Sep 1, 2016 1:32 PM Flag

    so, kad, you are buying at $5 and below? Well, good luck :-) But what if current sellers are also very lucky because they will avoid possible -50% losses in case of Prana failure to lift PCH for Ph3 HD? Prana CEO can't infinitely feed holders with promises like "we are working with FDA", "we are preparing a Complete Response" etc. At some point (may be after Feb 2017 - 24 months anniversary of PCH start) such promises will become just laughable :-)
    So, what is your prediction of pps crash in case of FDA rejection of PRAN Complete Response for lift PCH with 250 mg PBT2 dosing?

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Aug 31, 2016 1:45 PM Flag

    LOL! Still dreaming about promised pps $18? How about $1.8 after a failure to lift FDA PCH for Ph3 HD?

    Sentiment: Strong Sell

  • positive FDA response for their Complete Response that they were preparing during 18-months. In case of rejection PRAN is preparing some sweet pills for desperate holders: Europe trial for PBT2 and possible Phase I for PD drug.
    Any way, news about rejection of Complete Response will hit this stock very hard: at least -30-40% losses for holders at average $5.8.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Aug 29, 2016 4:20 PM Flag

    wow! "political nature of FDA PCH" for HD drug? :-) kad, you just added one more conspiracy theory :-)
    I see this PBT2 EU trial for HD only as a buckup plan in case if FDA rejects a Complete Response from PRAN to lift PCH for 250 mg daily dose of PBT2. Looks like that PRAN CEO already know that FDA will not agree with their arguments about PBT2 safety for HD patients in Ph3 trial. Failure to lift PCH will hit very hard - especially holders that bought stock recently at $5.80 average. -30-40% pps drop will be very modest prediction for such "update" and Prana's last hope is that EMA approval for Ph3 HD will at least save pps from decline below $1.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Aug 29, 2016 1:13 PM Flag

    usual BS: "we are developing...", "process is ongoing" :-)
    Only naive investors will buy such stupid "updates" :-)
    One thing is interesting: potential Europe HD trial if FDA reject PRAN safety data package. The rejection will crash PRAN pps to $3 and below but PRAN CEO wants to save it by new lie: potential clinical HD trial in Europe. Well, they know how to fool naive investors and prevent massive sell off :-)
    Other parts are also not so optimistic: cash positions are melting, PRAN management have only 2-3 years of happy life :-)

    Sentiment: Strong Sell

  • Reply to

    NO News and NO Profit = $6.00 range

    by raremerlin Aug 15, 2016 9:41 AM
    biotech_invest biotech_invest Aug 25, 2016 1:46 PM Flag

    here you are 100% wrong - ORMP pills are not the first oral insulin (EMIS tablets were the first) and the decreasing of glycated hemoglobin (HbA1c) was very modest to selebrate a success. EMIS oral insulin tablets also decreased HbA1c but only in one treated group which take tablets with highest insulin amount (8 mg per tablet). And the decreasing was 1% (from level 8-8.5% to 7-7.5%).
    Any way ORMP scam is still good to make some money (on both next run up during Phase III and failure of this trial). Just wait for right moment :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Aug 25, 2016 9:18 AM Flag

    kad, your naive attempts to pump PRAN are making me LOL :-) Look at August 26, 2015 pps - it was $5.58. And yesterday pps was $5.41. Where you see any gain for longs?
    Jan-Feb 2016(when pps was $2.80-3) average daily volumes were 15-20k so only a few % of PRAN holders have shares with such low pps. And most likely they already sold them at recent spike $5.80-6. And right now those new holders at $5.80-6 (4.4M shares) will have even bigger losses when PRAN CEO will notify holders that they can't lift PCH for Phase 3 HD.
    Keep pumping this scam :-) Only naive idiots will believe in your fairy tale stories about very profitable biotech Prana.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Aug 23, 2016 7:50 PM Flag

    So, kad, you started to compare DNDN with PRAN? :-) It's too delusional :-)
    Why you are not saying that 4.4M shares were ordered by some funds/institutions that suddenly believes in PRAN AD/HD/PD drugs? May we will see it very soon in reports :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Aug 23, 2016 11:42 AM Flag

    LOL! Who will do a churning with such hopeless stock? PRAN has a couple of MMs but it's very unlikely that they will play with PRAN. And BTW a churning is an illegal and unethical practice that violates SEC rules and securities laws.
    Simplest explanation of 2 days spike in volume will be a big BUY orders from new buyers. They ordered big volumes but with limited price around $6 and got it because many PRAN holders were happy to get $1 (in before 1:6 RS price) and cut their losses with this scam. Practically all 9M Prana outstanding shares are owned by small retail investors. May be just by several thousands so if it's 5000 holders average volume for each will be just 1800 shares, with 10000 - 900 shares per investor. 99% of PRAN have losses -30-70% and they know that their losses will only increase. Hope for lift of PCH is melting so PRAN holders use any possibility to sell.
    New holders at average $5.80 will also sell but later when they will have -15-20% losses.

    Sentiment: Strong Sell

SNY
37.995-0.355(-0.93%)1:19 PMEDT